Company intelligence / Profile preview

Lobsor Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Lobsor Pharmaceuticals has developed Lecigon, a proprietary gel formulation combining levodopa, carbidopa, and entacapone for continuous intestinal infusion in advanced Parkinson’s disease. Lecigon is approved in Sweden and some European markets. The therapy aims to improve motor fluctuations and reduce side effects associated with high-dose levodopa by enabling lower dosing through the addition of entacapone. Clinical results indicate improved convenience, reduced 3‑OMD metabolite levels, and better quality of life for patients[1][7][10].

Therapeutic areas: Neurology
Modalities: Small moleculeGel formulation
Industry: Biotech

Drug pipeline

1 asset

Lecigon

Partnerships

Recipharm AB (manufacturing partner)[8]Bioglan/Reig Jofre group (exclusive manufacturing for Europe)[9]TFS International (clinical research organization partner)[3]

Beyond the preview

Go deeper on Lobsor Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lobsor Pharmaceuticals.